Schroders Capital UK Innovation LTAF Announces Biopharma Investment

Schroders Capital, the $99.3bn private markets business of Schroders, announces today that its UK Innovation Long-Term Asset Fund (LTAF) has invested in Draig Therapeutics, a clinical-stage biopharma company aiming to transform the treatment of neuropsychiatric diseases. The UK is Europe‘s largest venture capital market and… Read More
Read more in: Global | Tagged investments, private markets, schroders capital, uk, united kingdom